Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma

Autor: Branko Zakotnik, Katja Goričar, Janez Lamovec, Viljem Kovač, Vita Dolžan, Janez Jazbec
Rok vydání: 2015
Předmět:
Zdroj: Cancer Epidemiology. 39:182-188
ISSN: 1877-7821
DOI: 10.1016/j.canep.2014.12.009
Popis: Background Osteosarcoma patients are commonly treated with cisplatin-based preoperative and postoperative chemotherapy. Cisplatin binds to DNA and forms both intrastrand and interstrand crosslinks, inhibiting DNA replication. Glutathione-S-transferases (GSTs) participate in cisplatin detoxification, while several independent DNA repair mechanisms repair cisplatin-induced lesions. The aim of our study was to investigate the influence of genetic variability of DNA repair mechanisms and GSTs on efficacy and toxicity of cisplatin-based chemotherapy in osteosarcoma patients. Methods A total of 66 osteosarcoma patients were genotyped for ERCC1 , ERCC2 , NBN , RAD51 , XRCC3 , and GSTP1 polymorphisms, as well as GSTM1 and GSTT1 gene deletion. We determined the influence of polymorphisms on survival and treatment outcome using Cox regression and logistic regression. Results Carriers of at least one polymorphic ERCC2 rs1799793 allele had longer event-free survival (EFS) ( P =0.006; hazard ratio (HR)=0.28; 95% confidence interval (CI)=0.11–0.70). Polymorphic GSTP1 rs1138272 allele was associated with both shorter EFS and OS ( P =0.005; HR=3.67; 95%CI=1.47–9.16; and P =0.004; HR=3.52; 95%CI=1.51–8.22, respectively). Compared to the reference NBN CAA haplotype, NBN CGA haplotype was associated with shorter EFS ( P =0.001; HR=4.12; 95%CI=1.77–9.56). Conclusions Our results suggest that DNA repair polymorphisms and GST polymorphisms could be used as predictive factors for cisplatin-based chemotherapy in osteosarcoma patients and could contribute to treatment personalization.
Databáze: OpenAIRE
Externí odkaz: